Malignant tumours (B), benign vs. malignant tumours (C), mucinous vs. serous benign and borderline tumours
Malignant tumours (B), benign vs. malignant tumours (C), mucinous vs. serous benign and borderline tumours (D), and serous vs. endometrioid malignant tumours (E).danger of IL-17 Antagonist custom synthesis ovarian cancer…